Alkermes plc Total Assets
Alkermes plc total assets. Based on the latest financial reports, Alkermes plc (8AK) holds total assets worth €4.26 Billion EUR (≈ $4.98 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 8AK cash flow conversion for how efficiently the company converts equity into cash flow.
Total Assets of Alkermes plc (2013–2025)
Total assets of Alkermes plc from 2013 to 2025. This chart illustrates how Alkermes plc's total assets have evolved over time, based on quarterly financial data. See 8AK stock price for real-time trading data and today's change.
Alkermes plc - Asset Composition Analysis
Alkermes plc Total Assets Breakdown (December 2025)
Alkermes plc total assets breakdown as of December 2025. Alkermes plc's total assets of €4.26 Billion consist of 77.6% current assets and 22.4% non-current assets. Explore working capital to net assets of Alkermes plc to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 15.6% |
| Accounts Receivable | €268.62 Million | 10.8% |
| Inventory | €196.62 Million | 7.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €815.00K | 0.0% |
| Goodwill | €83.03 Million | 3.3% |
Asset Composition Trend (2013–2025)
This chart illustrates how Alkermes plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alkermes plc's current assets represent 77.6% of total assets in 2025, an increase from 36.1% in 2013.
- Cash Position: Cash and equivalents constituted 15.6% of total assets in 2025, up from 10.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 39.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 10.8% of total assets.
Alkermes plc Competitors by Total Assets
Key competitors of Alkermes plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
|
China | CN¥2.53 Billion |
|
Dezhan HealthCare Co Ltd
SHE:000813
|
China | CN¥4.77 Billion |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907
|
China | CN¥2.00 Billion |
Alkermes plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.27 | 3.33 | 3.73 |
| Quick Ratio | 1.70 | 2.92 | 3.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €759.14 Million | €1.04 Billion | €578.68 Million |
Alkermes plc - Advanced Valuation Insights
This section examines the relationship between Alkermes plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.22 |
| Latest Market Cap to Assets Ratio | 2.67 |
| Asset Growth Rate (YoY) | 21.0% |
| Total Assets | €2.49 Billion |
| Market Capitalization | $6.65 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Alkermes plc's assets at a significant premium (2.67x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Alkermes plc's assets grew by 21.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Alkermes plc (2013–2025)
The table below shows the annual total assets of Alkermes plc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €2.49 Billion ≈ $2.91 Billion |
+20.99% |
| 2024-12-31 | €2.06 Billion ≈ $2.40 Billion |
-3.78% |
| 2023-12-31 | €2.14 Billion ≈ $2.50 Billion |
+8.77% |
| 2022-12-31 | €1.96 Billion ≈ $2.30 Billion |
-2.99% |
| 2021-12-31 | €2.02 Billion ≈ $2.37 Billion |
+10.93% |
| 2018-12-31 | €1.83 Billion ≈ $2.13 Billion |
+1.55% |
| 2017-12-31 | €1.80 Billion ≈ $2.10 Billion |
+4.10% |
| 2016-12-31 | €1.73 Billion ≈ $2.02 Billion |
-6.97% |
| 2015-12-31 | €1.86 Billion ≈ $2.17 Billion |
-3.30% |
| 2014-12-31 | €1.92 Billion ≈ $2.24 Billion |
+21.65% |
| 2013-12-31 | €1.58 Billion ≈ $1.84 Billion |
-- |
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more